Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon (Le Kremlin-Bicêtre, France), P. Clerson (Roubaix, France), V. Cottin (Lyon, France), P. Degroote (Lille, France), G. Prevot (Toulouse, France), L. Savale (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), A. Chaouat (Nancy, France), C. Dromer (Bordeaux, France), A. Bourdin (Montpellier, France), S. Renard (Marseille, France), E. Bergot (Caen, France), C. Pison (Grenoble, France), F. Bauer (Rouen, France), C. Dauphin (Clermont Ferrand, France), M. Reynaud Gaubert (Marseille, France), D. Montani (Le Kremlin-Bicêtre, France), G. Simonneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France). A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study. 497

Member's Comments

No comment yet.

Related content which might interest you: Validation of two predictive models for survival in pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 152-164 Year: 2015 Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Hemodynamic predictors of survival in scleroderma related pulmonary hypertension: a single center study Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 The effect of long-term specific therapy on clinical outcome, echocardiographic and sympatho-vagal balance as assessed by heart rate variability in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 The use of non-invasive stroke volume measurement to assess treatment response in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Towards prognostic biomarkers in pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 799-801 Year: 2012 A critical analysis of survival in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:218-222 Year: 2012 The study of risk in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:234-238 Year: 2012 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Mobile spiroergometry for prediction of survival in pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Surrogate markers of right ventricular adaptation better predict long-term survival in patients with PAH than traditional prognostic variables Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Determinants and prognostic value of kidney disease in pulmonary arterial hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Early improvements predict outcomes in pulmonary arterial hypertension Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease Source: Eur Respir J, 54 (3) 1802435; 10.1183/13993003.02435-2018 Year: 2019 Survival in pulmonary arterial hypertension (PAH): impact of 3 different periods of management Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 How to detect disease progression in pulmonary arterial hypertension Source: Eur Respir Rev 2012; 21: 40-47 Year: 2012 Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017 Year: 2017